<DOC>
	<DOCNO>NCT02194231</DOCNO>
	<brief_summary>The purpose study determine whether trabectedin effective treatment malignant pleural mesothelioma ( MPM ) .</brief_summary>
	<brief_title>ATREUS - Phase II Study Activity Trabectedin Patients With Malignant Pleural Mesothelioma ( MPM )</brief_title>
	<detailed_description>There approved agent second-line treatment MPM patient fail first line pemetrexed plus platinum derivative regimen . Chemotherapy option limit include gemcitabine , vinorelbine antifolate compound . The role second-line chemotherapy therefore yet establish second-line patient population consider suitable phase II study investigational agent . Trabectedin originally natural marine product , obtain semisynthetic process , induces delay S phase progression blockade G2 phase cell cycle mode action seem different DNA-damaging agent ( see citation ) . Although exact mechanism action trabectedin fully elucidate yet , appear unique compare anticancer agent ( see citation ) . Trabectedin bind N2 guanine minor groove DNA , cause bend minor groove towards major groove . In randomised clinical trial metastatic leiomyosarcoma liposarcoma recurrent platinum-sensitive ovarian cancer , trabectedin infuse 1.5 mg/m2 24-hour infusion 1.3 mg/m2 3 hour infusion every 3 week ( see citation ) . Balancing efficacy safety short infusion preferable clinical practice . In soft tissue sarcoma response rate exceed 10 % , however , trabectedin show provide disease control , progression arrest rate exceed 50 % progression-free survival rate exceed 20 % 6 month . In pre-treated ovarian cancer objective response rate 30 % median time disease progression 5.7 month . Trabectedin extensively employ MPM , however phase I study , objective response heavily pre-treated mesothelioma patient see . The present study aim evaluate activity trabectedin MPM patient candidate radical surgery . This option particular interest due lack valid therapeutic option . Translational study perform identify factor predictive activity trabectedin MPM .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>1 . Histologically proven unresectable MPM . In order make reproducible diagnosis , particular regard biphasic MPM , histology must derive transthoracic biopsy ( least 3 representative sample ) videothoracoscopy ( least 5 representative sample ) 2 . Age &gt; 18 year 3 . Performance status 01 ( ECOG ) 4 . Measurable disease ( CTPET ) accord RECIST criterion modify malignant pleural mesothelioma 5 . Not one previous chemotherapy course ( consist pemetrexed plus platinum derivative ) , exclude adjuvant therapy PFS &lt; 12 month 6 . A minimum 3 week since previous tumour direct therapy 7 . Recovery toxic effect previous therapy NCI CTC AE Grade 01 8 . Patients receive palliative radiation eligible &lt; 30 % bone marrow irradiate normal haematological function completely regain 9 . Haematologic variable : haemoglobin ≥ 9 g/dL , Absolute neutrophil count ( ANC ) ≥ 1,500/μL Platelet count ≥ 100,000/μL 10 . Serum creatinine ≤1.5 mg/dL creatinine clearance ≥ 30 mL/min 11 . Creatinine phosphokinase ( CPK ) ≤ 2.5 ULN 12 . Hepatic function variable : Total bilirubin ≤ ULN , Total alkaline phosphatase ≤ 2.5 ULN &gt; 2.5 ULN alkaline phosphatase liver fraction GGT 5 ' nucleotidase must determine ≤ ULN , AST ( serum aspartate transaminase [ SGOT ] ) ALT ( serum alaninetransaminase [ SGPT ] ) must ≤ 2.5 x ULN , Albumin ≥ 25 g/L 13 . Signed informed consent 14 . Adequate contraceptive method male patient whose partner childbearing age/potential , study three month end treatment 1 . Radiotherapy curative intent thoracic wall ( concomitant prior chemotherapy ) 2 . Uncompensated diabetes mellitus condition absolutely contraindicate dexamethasone ( used premedication ) 3 . Patients enrol study experimental drug 4 . Women childbearing age/potential 5 . Prior exposure trabectedin 6 . History malignancy ( except basal cell carcinoma cervical carcinoma situ , adequately treat ) , unless remission 5 year judge negligible potential relapse 7 . Active viral hepatitis chronic liver disease 8 . Unstable cardiac condition , include congestive heart failure angina pectoris , myocardial infarction within one year enrolment , uncontrolled arterial hypertension arrhythmias 9 . Active major infection 10 . Other serious concomitant illness 11 . Brain / leptomeningeal involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>MPM</keyword>
	<keyword>Trabectedin</keyword>
</DOC>